Ravindran Kanesvaran

Research interests

Publications

• Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

  Annals of Oncology · 2024 · https://doi.org/10.1016/j.annonc.2024.05.537

• Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

  European Journal of Cancer · 2023 · https://doi.org/10.1016/j.ejca.2023.02.018

• Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

  European Urology · 2022 · 10.1016/j.eururo.2022.11.002

• Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021

  European Urology · 2022 · https://doi.org/10.1016/j.eururo.2022.04.002

• Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival

  JAMA Network Open · 2021 · https://doi.org/10.1001/jamanetworkopen.2020.21869

• Assessing mentoring: A scoping review of mentoring assessment tools in internal medicine between 1990 and 2019

  PLoS ONE · 2020 · 10.1371/journal.pone.0232511

• Priorities for the global advancement of care for older adults with cancer: an update of the International Society of Geriatric Oncology Priorities Initiative

  The Lancet Oncology · 2020 · 10.1016/s1470-2045(20)30473-3

• Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019

  European Urology · 2020 · https://doi.org/10.1016/j.eururo.2020.01.012

• Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus

  Annals of Oncology · 2020 · https://doi.org/10.1016/j.annonc.2020.07.010

• Linguistic validation of the simplified Chinese version of the US National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE™)

  BMC Cancer · 2020 · https://doi.org/10.1186/s12885-020-07631-5

• Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer

  Journal of Clinical Oncology · 2019 · 10.1200/jco.18.00177

• Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis

  Lung Cancer · 2019 · 10.1016/j.lungcan.2019.11.022

• Global geriatric oncology: Achievements and challenges

  Journal of Geriatric Oncology · 2017 · 10.1016/j.jgo.2017.06.001

• Correction: Corrigendum: Patient-specific hepatocyte-like cells derived from induced pluripotent stem cells model pazopanib-mediated hepatotoxicity

  Scientific Reports · 2017 · https://doi.org/10.1038/srep46391

• Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy

  European Urology · 2016 · 10.1016/j.eururo.2016.02.033

• The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study

  The Lancet Oncology · 2015 · https://doi.org/10.1016/s1470-2045(14)71222-7

• Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations

  Annals of Oncology · 2014 · https://doi.org/10.1093/annonc/mdu210

• Analysis of Prognostic Factors of Comprehensive Geriatric Assessment and Development of a Clinical Scoring System in Elderly Asian Patients With Cancer

  Journal of Clinical Oncology · 2011 · https://doi.org/10.1200/jco.2010.32.0796

Current projects

No projects listed.